In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, INmune Bio Inc (NASDAQ: INMB) closed at $2.05 down -5.32% from its previous closing price of $2.16. In other words, the price has decreased by -$5.32 from its previous closing price. On the day, 1.57 million shares were traded. INMB stock price reached its highest trading level at $2.2099 during the session, while it also had its lowest trading level at $1.945.
Ratios:
For a deeper understanding of INmune Bio Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.20 and its Current Ratio is at 4.20. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On January 28, 2025, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $23.Rodman & Renshaw initiated its Buy rating on January 28, 2025, with a $23 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 30 ’24 when Moss David J bought 10,000 shares for $5.29 per share. The transaction valued at 52,868 led to the insider holds 1,285,869 shares of the business.
Tesi Raymond Joseph bought 15,380 shares of INMB for $98,048 on Sep 12 ’24. The President and CEO now owns 1,554,106 shares after completing the transaction at $6.38 per share. On Sep 12 ’24, another insider, Moss David J, who serves as the Chief Financial Officer of the company, bought 7,690 shares for $6.38 each. As a result, the insider paid 49,024 and bolstered with 1,275,869 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INMB now has a Market Capitalization of 54366940 and an Enterprise Value of 21443852. For the stock, the TTM Price-to-Sale (P/S) ratio is 1087.26 while its Price-to-Book (P/B) ratio in mrq is 1.88. Its current Enterprise Value per Revenue stands at 428.877.
Stock Price History:
The Beta on a monthly basis for INMB is 1.04, which has changed by -0.70189506 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, INMB has reached a high of $11.64, while it has fallen to a 52-week low of $1.89. The 50-Day Moving Average of the stock is -34.44%, while the 200-Day Moving Average is calculated to be -66.44%.
Shares Statistics:
For the past three months, INMB has traded an average of 3.40M shares per day and 813660 over the past ten days. A total of 26.59M shares are outstanding, with a floating share count of 18.90M. Insiders hold about 28.90% of the company’s shares, while institutions hold 21.23% stake in the company. Shares short for INMB as of 1755216000 were 5330331 with a Short Ratio of 1.57, compared to 1752537600 on 5527466. Therefore, it implies a Short% of Shares Outstanding of 5330331 and a Short% of Float of 24.159999.
Earnings Estimates
The firm’s stock currently is rated by 2.0 analysts. The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.31 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.22 and -$1.59 for the fiscal current year, implying an average EPS of -$1.44. EPS for the following year is -$1.14, with 4.0 analysts recommending between -$0.72 and -$1.3.
